NEW YORK (GenomeWeb News) – eBioscience recorded $70.9 million in revenues during 2011, leading to a profit of $9.6 million, Affymetrix disclosed in a regulatory filing today.

Waiting to complete its $315 million buy of the San Diego-based flow cytometry and immunoassay reagents firm, Affy today said in a document filed with the US Securities and Exchange Commission that eBioscience's 2011 revenues increased 9 percent over 2010 revenues of $65.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.